What the research studies say
about medical uses
This supplement may be helpful in asthma, inflammatory bowel disease, osteoarthritis and rheumatoid arthritis.
Halpern GM. Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus. Allerg Immunol. 2000.
Couch RA, Ormrod DJ. Anti-inflammatory activity in fractionated extracts of the green-lipped mussel. N Z Med J. 1982.
Bierer TL, Bui LM. Improvement of arthritic signs in dogs fed green-lipped mussel (Perna canaliculus). J Nutr. 2002.
Asthma, is there a benefit?
Asthma is a chronic inflammatory disease of the airways mediated, at least in part, by leukotrienes and other lipid mediators. Experimental studies have shown that lipid extract of New Zealand green-lipped mussel, Perna canaliculus, is effective in inhibiting 5'-lipoxygenase and cyclo-oxygenase pathways responsible for production of eicosanoids, including leukotrienes and prostaglandins. The aim of this study was to assess its effect on symptoms, peak expiratory flow (PEF) and hydrogen peroxide (H2O2) in expired breath condensate as a marker of airway inflammation in patients with steroid-naive asthma in a double-blind randomised, placebo-controlled clinical trial. Forty six patients with asthma received two capsules of marine lipid extract or placebo b.i.d for 8 weeks. Each capsule of lyprinol contained 50 mg omega-3 polyunsaturated fatty acids and 100 mg olive oil, whereas placebo capsules contained only 150 mg olive oil. There was a significant decrease in daytime wheeze, the concentration of exhaled H2O2 and an increase in morning PEF in the lyprinol group compared to the placebo group. There were no significant side-effects. The authors conclude that Lyprinol, the marine lipid extract of New Zealand green-lipped mussel may have some beneficial effect in patients with atopic asthma.
Emerlyanov, A. Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial. Eur Respir J. 2002.
Lyprinol ( stabilised lipid extract of New Zealand green-lipped mussel ): a potential preventative treatment modality for inflammatory bowel disease.
J Gastroenterol. 2005. Child Health Research Institute, Women's and Children's Hospital, North Adelaide, South Australia, Australia.
Lyprinol (Pharmalink International), the stabilised lipid extract of the New Zealand green-lipped mussel, is currently used to relieve symptoms of arthritis. We investigated the effect of pretreatment with Lyprinol on experimentally induced inflammatory bowel disease in mice. Conclusions: These findings provide preliminary evidence that this treatment may be potentially useful in ameliorating symptoms of inflammatory bowel disease. The benefit, however, is unlikely to be due to the omega-3 fatty acid content.
Lyprinol: a potential preventive treatment for inflammatory bowel
Asia Pac J Clin Nutr. 2004.
Fish oil and the stabilised lipid extract of New Zealand Green Lipped Mussel are considered beneficial in treating arthritis and other inflammatory conditions. Unlike fish oil, it is uncertain whether any benefit seen with Lyprinol is due to its omega-3 fatty acid content. We compared the effect of Lyprinol and fish oil pre-treatments on experimental induction of IBD in mice. These findings indicate that Lyprinol may be potentially useful in ameliorating symptoms of IBD. The lack of effect of fish oil indicates that the benefit of this product is attributable to components of the stabilised lipid extract other than its omega 3 content.
Testimonial received 2011
I started taking Lyprinol for the very painful and chronic IBS and Crohn's disease and for me it was like a magic bullet. I took it approximately one year with dramatic results.
A lipid-rich extract, prepared by supercritical fluid (CO2) extraction of freeze-dried stabilized New Zealand green-lipped mussel powder ( Lyprinol ) has shown significant anti-inflammatory activity when given to animals and humans. When treated p.o. with Lyprinol, Wistar and Dark Agouti rats developed neither adjuvant-induced polyarthritis or collagen(II)-induced auto-allergic arthritis. This was achieved with doses < NSAIDs, and 200 times < of other seed or fish oils. Lyprinol subfractions inhibited LTB4 biosynthesis by PMN in vitro, and PGE2 production by activated macrophages. Much of this anti inflammatory activity was associated with omega-3 PUFAs and natural antioxidants [e.g. carotenoids]. In contrast to NSAIDs, Lyprinol is non-gastro toxic in disease-stressed rats at 300 mg/kg p.o., and does not affect platelet aggregation [human, rat]. Clinical studies, either controlled or randomized, have demonstrated very significant anti inflammatory activity in patients with osteoarthritis, rheumatoid arthritis, asthma, and other inflammatory conditions. Lyprinol is a reproducible, stable source of bioactive lipids with much greater potency than plant/marine oils currently used as nutritional supplements to ameliorate signs of inflammation.
Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand
green-lipped mussel in patients with osteoarthritis of the
hip and knee: a multicenter 2-month clinical trial.
Allerg Immunol. 2003.
To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with arthritis. In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects. Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial. Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.
Rheumatoid Arthritis help
RA patients who took Lyprinol were able to reduce their medications.
Efficacy and tolerability of a
combination of Lyprinol and high concentrations of EPA and DHA in inflammatory
Adv Ther. 2004.
This 12-week drug-monitoring study was conducted to evaluate the efficacy of Sanhelios Mussel Lyprinol Lipid Complex on 50 adult men and women with inflammatory rheumatoid arthritis. A total of 34 patients required drug therapy before and during the study. By the end of the Lyprinol study, 21 (62%) patients were able to reduce their dosage and 13 were able to terminate drug therapy. At the end of the Lyprinol treatment period, 38% were regarded symptom free, and the number of patients with severe pain decreased significantly from 60% at baseline to 25% at the completion of the trial. A significant effect was observed for each investigated parameter. The special combination of Lyprinol and omega-3 fatty acids was generally very well tolerated. This dietary supplement may therefore be considered an effective and well-tolerated component of treatment regimens for inflammatory rheumatoid arthritis.
Side effects, safety, danger
As of 2014, I am not aware of green lipped mussel side effects reported in scientific journals.
Q. I am allergic to shellfish, would Lyprinol cause an allergic reaction to people who are allergic to shellfish?
A. Lyprinol is extracted from the New Zealand green-lipped mussel which is a shellfish. Shellfish allergies can be caused by certain proteins in seafood. Since Lyprinol oil does not have protein, the risk of shellfish allergy from taking Lyprinol should not occur. As of 2009 no Lyprinol allergy has been reported in the medical literature. We suggest you consult with your healthcare provider for the final decision as to the appropriateness of Lyprinol for your particular health condition.
I am allergic to bivalve mollusks, ie. oysters,
mussels, scallops. May I take Lyprinol?
I am not sure exactly how the manufacturing process is done to know whether there are any residues of shellfish protein that could be a problem to those with severe allergies to shellfish. Thus far I have not heard of anyone having a bad reaction or an allergy to Lyprinol. It is possible that some shellfish residues are left over.
A lipid extract of Perna canaliculus affects the expression of pro-inflammatory cytokines in a rat adjuvant-induced arthritis model.
Eur Ann Allergy Clin Immunol. 2008.
The lipid extract of Perna canaliculus, New Zealand green-lipped mussel, is known for its anti-inflammatory effects in animal models and in human controlled studies (arthritis; asthma). As a follow-up of its effects on pain in a rat model of adjuvant-induced arthritis, we studied its effects on the production of cytokines known to be associated with inflammation (IL-6, IL-1alpha TNF-alpha, IFN-gamma). Feeding with Lyprinol was associated with significantly decreased expression levels of TNF-alpha and IFN-gamma when compared to Naproxen (positive control) and, even more when compared with sham and extra-virgin olive oil (negative control).
Lyprinol -- is it a Useful Anti-inflammatory Agent?
Evid Based Complement Alternat Med. 2009.
The Food and Drug Administration have recently warned Lyprinol USA about their extravagant anti-inflammatory claims appearing on the web. These claims are put to thorough review. Lyprinol does have anti-inflammatory mechanisms, and has anti-inflammatory effects in some animal models of inflammation. It may have benefits in dogs with arthritis. There are design problems with the clinical trials of Lyprinol in humans as an anti-inflammatory agent in osteoarthritis and rheumatoid arthritis, making it difficult to give a definite answer to how effective it is in these conditions, but any benefit is small. Lyprinol also has a small benefit in atopic allergy. No adverse effects have been reported with Lyprinol. Thus, although it is difficult to conclude whether it does much good, it can be concluded that it probably does no major harm.